India’s strategy is in stark contrast to what we are seeing in the US, which seems to be directed toward winning the race for the world’s first billion-dollar antidote. Except for a handful of initiatives in the Big Pharma world, we are witnessing knowledge competition rather than knowledge collaboration. Instead of joining forces, companies are trying to outsmart each other. The focus is on beating the competitor, not the virus. The motivation is profits, not patient lives.
